[go: up one dir, main page]

MX2018016424A - Formulaciones de deposito. - Google Patents

Formulaciones de deposito.

Info

Publication number
MX2018016424A
MX2018016424A MX2018016424A MX2018016424A MX2018016424A MX 2018016424 A MX2018016424 A MX 2018016424A MX 2018016424 A MX2018016424 A MX 2018016424A MX 2018016424 A MX2018016424 A MX 2018016424A MX 2018016424 A MX2018016424 A MX 2018016424A
Authority
MX
Mexico
Prior art keywords
depot formulations
compositions
manufacture
disclosed
methods
Prior art date
Application number
MX2018016424A
Other languages
English (en)
Other versions
MX387477B (es
Inventor
Yamada Kazuhito
Matsumoto Naoki
Tamraz Wilma
Ching Lin Su Huey-
Lin Weiqi
Mudumba Sreenivasu
Okabe Komei
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2018016424A publication Critical patent/MX2018016424A/es
Publication of MX387477B publication Critical patent/MX387477B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/02—Monohydroxylic acyclic alcohols
    • C07C31/08—Ethanol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/12—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen composiciones farmacéuticas que comprenden un ingrediente farmacéutico activo, un material portador líquido de alta viscosidad, un solvente hidrófobo y un solvente hidrófilo. También se describen métodos de fabricación y de uso de las composiciones. Las composiciones son adecuadas para su uso, por ejemplo, como formulaciones de depósito.
MX2018016424A 2016-06-30 2017-06-29 Formulaciones de depósito. MX387477B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356613P 2016-06-30 2016-06-30
US201662440658P 2016-12-30 2016-12-30
PCT/US2017/039968 WO2018005777A1 (en) 2016-06-30 2017-06-29 Depot formulations

Publications (2)

Publication Number Publication Date
MX2018016424A true MX2018016424A (es) 2019-08-12
MX387477B MX387477B (es) 2025-03-18

Family

ID=60786467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016424A MX387477B (es) 2016-06-30 2017-06-29 Formulaciones de depósito.

Country Status (16)

Country Link
US (2) US10668011B2 (es)
EP (1) EP3478285A4 (es)
JP (2) JP7051721B2 (es)
KR (1) KR20190025635A (es)
CN (2) CN115645399A (es)
AU (2) AU2017290143A1 (es)
BR (1) BR112018077259A2 (es)
CA (1) CA2972296A1 (es)
GE (1) GEP20207204B (es)
IL (1) IL263714A (es)
MX (1) MX387477B (es)
PH (1) PH12018502615A1 (es)
SG (1) SG11201810618QA (es)
TW (1) TWI765898B (es)
UA (1) UA124768C2 (es)
WO (2) WO2018005777A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2704813C2 (ru) * 2015-03-18 2019-10-31 Сантен Фармасьютикал Ко., Лтд. Фармацевтическая композиция с пролонгированным высвобождением
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
EP4670713A1 (en) 2018-05-01 2025-12-31 Chibi, Inc. LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL
WO2019213326A1 (en) * 2018-05-01 2019-11-07 Idrop, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
CA3141337A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
CN113117049A (zh) * 2019-12-31 2021-07-16 齐鲁制药有限公司 一种索玛鲁肽原位凝胶制剂及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
FI933471L (fi) 1991-12-19 1993-08-05 Mitsui Toatsu Chemicals Polyhydroxikarboxylsyra och foerfarande foer dess framstaellning
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
ATE287673T1 (de) 1995-06-07 2005-02-15 Southern Biosystems Inc Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
IL157531A0 (en) 2001-02-23 2004-03-28 Genentech Inc Erodible polymers for injection
DE60325742D1 (de) 2002-07-31 2009-02-26 Alza Corp Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen
ES2494791T3 (es) 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Uso de rapamicina para el tratamiento o prevención de la degeneración macular asociada a la edad
PL377333A1 (pl) 2002-11-06 2006-01-23 Alza Corporation Preparaty depot o kontrolowanym uwalnianiu
CA2507522C (en) 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
EP1622540A4 (en) 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
PT1809329E (pt) 2004-09-17 2012-03-29 Durect Corp Composição anestésica local prolongada contendo aibs
NZ554426A (en) 2004-10-01 2010-05-28 Ramscor Inc Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006102378A2 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CN1973822A (zh) 2006-12-20 2007-06-06 山东蓝金生物工程有限公司 一种含雷帕霉素的抗癌组合物
AU2007339280B2 (en) 2006-12-21 2013-12-05 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US20080287464A1 (en) 2007-05-18 2008-11-20 Wright Jeremy C Depot Formulations
WO2009023877A2 (en) 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
AU2009212373B2 (en) 2008-02-08 2013-10-03 Foresee Pharmaceuticals Co., Ltd. Non-polymeric compositions for controlled drug delivery
CA2760932A1 (en) 2009-05-04 2010-11-11 Thierry Nivaggioli Mtor pathway inhibitors for treating ocular disorders
EP2643009A4 (en) 2010-11-24 2015-04-01 Durect Corp COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
AU2012321101A1 (en) 2011-11-23 2013-06-06 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
CA2861348C (en) 2012-01-23 2017-07-04 Allergan, Inc. Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
CN105163719B (zh) 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
HK1220445A1 (zh) 2013-03-15 2017-05-05 Durect Corporation 具有摇溶性以及增强的溶解再现性和稳定性的组合物
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN105407896B (zh) 2013-05-24 2019-08-27 爱康生物科技有限公司 缓释的地塞米松在白内障手术后的炎症中的应用
EP3220887A1 (en) 2014-11-21 2017-09-27 Technical University of Denmark Gel formulations for local drug release
RU2704813C2 (ru) 2015-03-18 2019-10-31 Сантен Фармасьютикал Ко., Лтд. Фармацевтическая композиция с пролонгированным высвобождением
KR20180023945A (ko) 2015-07-01 2018-03-07 산텐 세이야꾸 가부시키가이샤 시트르산에스테르를 함유하는 데포제
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
US11013731B2 (en) 2017-01-06 2021-05-25 Santen Pharmaceutical Co., Ltd. Intratumoral administration of sirolimus for treatment of prostate cancer

Also Published As

Publication number Publication date
KR20190025635A (ko) 2019-03-11
AU2017290143A1 (en) 2019-02-21
EP3478285A1 (en) 2019-05-08
GEP20207204B (en) 2020-12-25
WO2019133735A1 (en) 2019-07-04
UA124768C2 (uk) 2021-11-17
TWI765898B (zh) 2022-06-01
CN109310680A (zh) 2019-02-05
JP7051721B2 (ja) 2022-04-11
CN115645399A (zh) 2023-01-31
CA2972296A1 (en) 2017-12-30
US20180000729A1 (en) 2018-01-04
SG11201810618QA (en) 2019-01-30
BR112018077259A2 (pt) 2019-06-18
GEAP202014989A (en) 2020-07-27
AU2023202823A1 (en) 2023-05-25
TW201811374A (zh) 2018-04-01
EP3478285A4 (en) 2020-07-22
JP2019526532A (ja) 2019-09-19
MX387477B (es) 2025-03-18
CN109310680B (zh) 2022-11-01
WO2018005777A1 (en) 2018-01-04
JP2022088568A (ja) 2022-06-14
IL263714A (en) 2019-01-31
US20200352852A1 (en) 2020-11-12
PH12018502615A1 (en) 2019-09-30
US10668011B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
MX2018016424A (es) Formulaciones de deposito.
AR113031A1 (es) Composiciones de nanopartículas lipídicas (lnp) que comprende arn
CO6690766A2 (es) Composiciones agrícolas líquidas de estabilidad mejorada, y procesos para elaborar dichas composiciones
MX2016013512A (es) Sistemas y metodos para el uso simultaneo del espectro dentro del espectro usado activamente.
UY34605A (es) Derivados de arilalquiloxipirimidina e insecticidas agrohortícolas que comprenden dichos derivados como principios activos, y método de uso de los mismos
BR122021026889A8 (pt) Formas cristalinas de base livre de sepiapterina e de sais dos mesmos, seu método de preparação, composições que as compreendem, uso dos mesmos e método de preparação de uma formulação líquida
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
MX2020008323A (es) Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino.
MX2020007896A (es) Material portador para la liberacion de uno o varios agentes activos en una formulacion para el cuidado del hogar.
MX2017008888A (es) Las composiciones para cabello y metodos de uso.
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
ZA201807446B (en) Improved drug formulations
AR109162A1 (es) Formulaciones estables de preservante para madera
CL2023001140A1 (es) Formulaciones de anticuerpos anti-pd-l1
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
CO2018001371A2 (es) Una giberelina líquida a concentración alta con bajo nivel de cov
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.
CL2018001653A1 (es) Concentrados en emulsión de compuestos lipofílicos
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
EA201991594A1 (ru) Депо-препарат
BR112018073649A2 (pt) agente de controle de espuma de poliéter, formulação agroquímica, e, processo para preparar uma formulação agroquímica.
MX2020004178A (es) Composiciones de cannabidiol y quitosano y métodos de uso de éstas.
CO2019000083A2 (es) Composiciones farmacéuticas